DAPAgliflozin for renal protection in heart transplant recipients. Rationale and design of the randomized controlled DAPARHT trial

Authors

Institutions

Publication Details

Journal
American Heart Journal
Published
2025-08-19
DOI
https://doi.org/10.1016/j.ahj.2025.08.010
Citations
1
Primary Topic
Renal Transplantation Outcomes and Treatments
Type
article
Field-Weighted Citation Impact
1.99
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

DAPAgliflozin for renal protection in heart transplant recipients. Rationale and design of the randomized controlled DAPARHT trial

Oscar Ö. Braun, Lars Gullestad, Kaspar Broch, Elisabeth Bjørkelund et al.
1 citations
American Heart Journal
Renal Transplantation Outcomes and Treatments
1.99
article

DAPAgliflozin for renal protection in heart transplant recipients. Rationale and design of the randomized controlled DAPARHT trial

Oscar Ö. Braun, Lars Gullestad, Kaspar Broch, Elisabeth Bjørkelund, Håvard Ravnestad, Olivier C. Manintveld, Ida Haugen Löfman, Kevin Damman, Mariusz K. Szymanski, Stine Holmen
article en
1 citations

Abstract

No abstract available for this paper.
American Heart JournalVol. 291
Oslo University Hospital (NO), University Medical Center Groningen (NL), Karolinska University Hospital (SE), University of Groningen (NL), University of Oslo (NO), Lund University (SE), Innlandet Hospital Trust (NO), Erasmus MC (NL), University Medical Center Utrecht (NL), Skåne University Hospital (SE)
Good health and well-being
Openalex Percentile: Top 13%
Renal Transplantation Outcomes and Treatments
1.99
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

DAPAgliflozin for renal protection in heart transplant recipients. Rationale and design of the randomized controlled DAPARHT trial — Oscar Ö. Braun, Lars Gullestad, et al. · American Heart Journal (2025) | TGRS Research Map | TGRS